Fate Therapeutics (FATE) Tops Q2 EPS by 13c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.33), $0.13 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Gold Fields weighs higher bid for Northern Star Resources - Bloomberg
• Parsons Corporation (PSN)1800 contracts of October 45 calls trade, share price down 1%
• Trump in meeting with AI leaders: we have big lead on AI and want to keep it